{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-022763","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.523503+00:00","generated_at":"2026-05-24T22:12:15.615463+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sagimet reports FY2024 net loss of $45.6M; advances denifanstat Phase 3 in MASH and TVB-3567 IND clearance","bullets":["Full year 2024 net loss $45.6M ($27.9M in 2023); R&D expense $38.4M, up from $19.8M.","Cash $158.7M at Dec 31, 2024; funded by Jan 2024 follow-on offering of 9M shares netting $104.7M.","Phase 3 denifanstat program for MASH initiated; patient screening expected 1H 2025; includes FASCINATE-3 and FASCINIT.","FDA granted Breakthrough Therapy designation for denifanstat in non-cirrhotic MASH with F2/F3 fibrosis.","IND cleared for TVB-3567, a second FASN inhibitor for acne; Phase 1 trial planned in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-022763","json":"https://secwatch.observer/filing/0001104659-25-022763.json","markdown":"https://secwatch.observer/filing/0001104659-25-022763.md","text":"https://secwatch.observer/filing/0001104659-25-022763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/0001104659-25-022763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/tm258742d4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:12:15.615463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}